Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...197198199200201202203204205206207208209»
  • ||||||||||  Trial completion:  NovaTears (clinicaltrials.gov) -  Mar 9, 2016   
    P=N/A,  N=25, Completed, 
    Recruiting --> Completed
  • ||||||||||  Trial completion, Enrollment change:  NovaTears (clinicaltrials.gov) -  Mar 9, 2016   
    P=N/A,  N=72, Completed, 
    Recruiting --> Completed Recruiting --> Completed | N=90 --> 72
  • ||||||||||  AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
    New P1 trial:  A Study of SHR6390 in Advanced Solid Tumor Patients (clinicaltrials.gov) -  Feb 17, 2016   
    P1,  N=40, Not yet recruiting, 
  • ||||||||||  famitinib (SHR 1020) / Jiangsu Hengrui Pharma
    Enrollment closed, Trial primary completion date:  A Study of Famitinib in Patients With Gastrointestinal Stromal Tumor (clinicaltrials.gov) -  Feb 2, 2016   
    P2,  N=88, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Jun 2016
  • ||||||||||  AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
    Enrollment closed, Trial primary completion date, First-in-human:  First-in-Human Single Ascending Dose of SHR0302 (clinicaltrials.gov) -  Jan 26, 2016   
    P1,  N=64, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Jun 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Jul 2016
  • ||||||||||  Vevye (cyclosporine ophthalmic solution) / Novaliq, Harrow Health
    Enrollment open:  CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED) (clinicaltrials.gov) -  Jan 15, 2016   
    P2,  N=200, Recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Jul 2016 Not yet recruiting --> Recruiting
  • ||||||||||  Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma, Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
    Trial primary completion date:  The Drug-drug Interaction of SHR3824 and SP2086 (clinicaltrials.gov) -  Nov 25, 2015   
    P1,  N=12, Recruiting, 
    Recruiting --> Active, not recruiting Trial primary completion date: Oct 2015 --> Jul 2015
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment open, Trial primary completion date:  A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients (clinicaltrials.gov) -  Nov 24, 2015   
    P1,  N=27, Recruiting, 
    Trial primary completion date: Oct 2015 --> Jul 2015 Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2015 --> Jul 2016
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Enrollment open, Metastases:  A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer (clinicaltrials.gov) -  Nov 19, 2015   
    P2/3,  N=66, Recruiting, 
    Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2015 --> Jul 2016 Not yet recruiting --> Recruiting
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Enrollment open, Metastases:  Apatinib for Metastatic Esophageal Cancer. (clinicaltrials.gov) -  Oct 22, 2015   
    P2,  N=29, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Trial completion, Trial primary completion date:  Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients (clinicaltrials.gov) -  Sep 9, 2015   
    P2a,  N=60, Completed, 
    Trial primary completion date: Nov 2016 --> Nov 2017 Active, not recruiting --> Completed | Trial primary completion date: Mar 2015 --> Jun 2014
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    New P2 trial, Metastases:  Apatinib for Metastatic Esophageal Cancer. (clinicaltrials.gov) -  Sep 9, 2015   
    P2,  N=29, Not yet recruiting, 
  • ||||||||||  Trial primary completion date:  NovaTears (clinicaltrials.gov) -  Aug 21, 2015   
    P=N/A,  N=30, Recruiting, 
    Phase classification: P4 --> P2/3 Trial primary completion date: Jun 2015 --> Dec 2015
  • ||||||||||  Trial primary completion date:  NovaTears (clinicaltrials.gov) -  Aug 21, 2015   
    P=N/A,  N=90, Recruiting, 
    Trial primary completion date: Jun 2015 --> Dec 2015 Trial primary completion date: May 2015 --> Dec 2015